Kodiak Sciences Reports Q2 2026 Results; Cash Runway Into 2027, Three Phase 3 Readouts Ahead
KOD has more than doubled off its 52-week low of $8.29.
Summary
Kodiak Sciences reported Q2 2026 results with a $65.6M net loss and $125.9M in cash, guiding runway into 2027. Three Phase 3 readouts are expected by year-end, starting with DAYBREAK in September.
Key Events · Earnings and Guidance · KOD
-
Q2 2026 Financial Results
Net loss of $65.6 million ($1.05 per share) versus $54.3 million a year ago. R&D expenses rose to $56.1 million from $42.8 million, driven by increased clinical and manufacturing activities.
-
Cash Position and Runway
Cash and cash equivalents of $125.9 million as of June 30, 2026, down from $209.9 million at year-end 2025. Management expects current cash to support operations into 2027.
-
Phase 3 Readout Timeline
DAYBREAK topline data for Zenkuda and KSI-501 in wet AMD expected September 2026. PEAK Pivotal Analysis 1 for KSI-101 in MESI expected December 2026. PEAK/PINNACLE Pivotal Analysis 2 expected Q2 2027.
-
Clinical Milestones Achieved
Completed enrollment of the first 300-patient cohort for PEAK Pivotal Analysis 1. First patients enrolled in the Phase 3 ALTO study of KSI-501 in diabetic macular edema.
Analysis · KOD · Life Sciences
Kodiak Sciences reported a Q2 2026 net loss of $65.6 million, with cash of $125.9 million expected to fund operations into 2027. The company has three Phase 3 readouts scheduled between September and December 2026, making the next few months pivotal for the stock. The cash position and runway guidance address the going concern warning from the prior quarter, but the increased R&D spend and ongoing losses keep the company dependent on clinical success.
At the time of this filing, KOD was trading at $40.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.29 to $47.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.